QUICKLINKS AND VIEW OPITONS
Contrave (300 mg Wellbutrin plus 50 mg naltrexone) causes weight loss of 6.6 percent in six months
Friday, March 30, 2007 2:36 am Email this article
Among patients who completed the six month study, those given Contrave, a drug combination of Wellbutrin (bupropion) and naltrexone, lost an average of 6.8 percent of their body weight in six months compared to 3.8 percent for those given Wellbutrin (bupropion) alone, 2.2 percent for for those given naltrexone alone, and 1 percent for patients given a placebo according a paper by Frank Greenway and George Bray (2007). (The placebo group was discontinued after four months.) Weight Loss
Weight Loss for all patients: 4% after four months, 5.2% after six months
Among all patients treated, including those who dropped out of the study early, the average weight loss was 4 percent after four months, and 5.2 percent after six months.
Note: These numbers slight different
Some of the percentages were taken from the paper by Greenway and Bray, while other percentages were taken from the company’s website.
Proof of Concept
This study was to prove the concept of this drug combination
The study was a proof of concept study according to Greenway and Bray, which means it was intented to prove that this combination causes more weight loss than either drug alone.
Naltrexone alone does not cause much weight loss
Naltrexone is a drug “used to help people who have a narcotic or alcohol addiction stay drug free.”
Greenway and Bray point out that naltrexone alone does not cause much weight loss.
Doses: 300 mg of Wellbutrin plus 50 mg of naltrexone
The doses used in this study were 300 mg of Wellbutrin (bupropion) plus 50 mg of immediate-release naltrexone.
Side Effects: 40% reported nausea
Forty percent (40 percent) of patients reported nausea which was due to the naltrexone.
Dropouts: 12% due to nausea
Approximately one-out-of-eight patients (12 percent) dropped out of the study due to nausea.
Subjects: 200 people
The study involved 200 people.
Contrave being developed by Orexigen Therapeutics
Contrave is being developed as a weight loss drug by a company in San Diego, California called Orexigen Therapeutics, the same company that is developing Excalia, which is a combination of Wellbutrin (bupropion) and Zonegran (zonisamide).
Greenway F, Bray G. Obesity medications: Where are we headed? Obesity Management. 2006 Oct, 2(5):181-85.
Orexigen Therapeutics, Inc.
12481 High Bluff Drive, Suite 160
San Diego, CA 92130
Data on Orexigen’s Clincal Trials
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.